首页> 外国专利> VITA, THE CHEMOTHERAPY TREATMENT FOR SEVERAL TYPES OF CANCER AND WITHOUT MAJOR AND MODERATE SIDE EFFECTS

VITA, THE CHEMOTHERAPY TREATMENT FOR SEVERAL TYPES OF CANCER AND WITHOUT MAJOR AND MODERATE SIDE EFFECTS

机译:VITA,几种类型且无主要和中度副作用的化疗药物

摘要

The innovative combination of different biological agents has made it possible to develop a treatment formula in the form of an intravenous infusion, for treating six (6) types of cancer, which are as follows: Ovarian cancer, testicular cancer, breast cancer, prostate cancer, stomach cancer, bladder cancer; The experimental procedure was prepared over the course of 40 months. The formula was tested in comparison with MYLAN's "cisplatin" treatment and TEVA's "5-fluorouracil" treatment. This treatment is favoured over the other treatments on the market because it provokes the cell death procedure in cancer cells for a shorter period than the cell death period when using the other formulae. Also, VITA's formulation provokes "selective" cell apoptosis without major and moderate negative effects. This formula is intended strictly for the pharmaceutical industry.
机译:不同生物制剂的创新组合使开发静脉输液形式的治疗配方成为可能,从而可以治疗六(6)种类型的癌症:卵巢癌,睾丸癌,乳腺癌,前列腺癌,胃癌,膀胱癌;在40个月的时间内准备了实验程序。将该配方与MYLAN的“顺铂”治疗和TEVA的“ 5-氟尿嘧啶”治疗进行了比较。这种治疗方法优于市场上的其他治疗方法,因为它引起癌细胞的细胞死亡过程的时间比使用其他配方时的细胞死亡时间短。同样,VITA的配方可激发“选择性”细胞凋亡,而没有主要和中等的负面影响。该配方严格用于制药行业。

著录项

  • 公开/公告号WO2020145905A1

    专利类型

  • 公开/公告日2020-07-16

    原文格式PDF

  • 申请/专利权人 GHIDHAOUI ABIR;

    申请/专利号WO2019TN00008

  • 发明设计人 GHIDHAOUI ABIR;

    申请日2019-02-19

  • 分类号A61K31/4745;A61K9;A61K31/136;A61K31/52;A61K31/675;A61P35;

  • 国家 WO

  • 入库时间 2022-08-21 11:10:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号